MeiraGTx(MGTX)
NEW YORK, NYBiotechnology
Focus: MeiraGTx is a New York-based gene therapy biotech focused on rare ophthalmic and CNS diseases, currently public on NASDAQ (MGTX). The company operates a diversified pipeline across retinal dystrophies, Parkinson's disease, and radiation-induced tissue damage.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
8+1 this month
Stable — net +1 jobs in 30d
5 added, 4 removed. Backfill posture.
Should You Work at MeiraGTx?
AI assessmentBest for scientists seeking exposure to next-generation gene therapy platforms; risky for those prioritizing financial stability or broad career mobility within a growing company.
Why Work Here
- Cutting-edge AAV gene therapy platform with 20 active clinical programs across multiple therapeutic areas offering deep technical expertise.
- Revenue growth trajectory ($14M FY2024 → $33M FY2025, 136% YoY) signals commercialization momentum despite R&D-heavy burn.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$33M
Pipeline & Clinical Trials
AAV OPTIRPE65
Leber Congenital Amaurosis (LCA)Clinical Trials (1)
NCT02946879Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
N/AHelp build intelligence for MeiraGTx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.